{
  "id": 10911451,
  "title": "Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial",
  "url": "https://urgent.news/2026/09/30/intravenous-hyaluronidase-expressing-oncolytic-adenovirus-with",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-30T00:00:00.000Z",
  "source": {
    "name": "Nature Medicine",
    "slug": "nature-medicine",
    "url": "https://www.nature.com/articles/s41591-026-04705-y"
  },
  "original_language": "en",
  "account": null,
  "summary": "Nature Medicine, Published online: 30 September 2026; doi:10.1038/s41591-026-04705-y In the randomized phase 2b VIRAGE trial, patients with treatment-naive metastatic pancreatic cancer received the hyaluronidase-expressing oncolytic adenovirus zabilugene almadenorepvec (VCN-01) intravenously with gemcitabine and nab-paclitaxel (GnP) or GnP alone, showing that VCN-01 plus GnP led to prolonged…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}